In contrast to the major families of small molecules and antibodies, cyclic peptides, as a
family of synthesizable macromolecules, have distinct biochemical and therapeutic …

Peptides and proteins are widely used to treat a range of medical conditions; however, they
often have to be injected and their effects are short-lived. These shortcomings of the native …

Glioblastoma multiforme (GBM) is one of the most fatal malignancies due to the existence of
blood-brain barrier (BBB) and the difficulty to maintain an effective drug accumulation in …

The practical application of nanoparticles (NPs) as chemotherapeutic drug delivery systems
is often hampered by issues such as poor circulation stability and targeting inefficiency …

Subunit vaccines have been investigated in over 1000 clinical trials of cancer
immunotherapy, but have shown limited efficacy. Nanovaccines may improve efficacy but …

Peptides have traditionally been perceived as poor drug candidates due to unfavorable
characteristics mainly regarding their pharmacokinetic behavior, including plasma stability …

For successful translation of targeting nanomedicines from bench to bedside, it is vital to
address their most common drawbacks namely rapid clearance and off-target accumulation …

Peptides and small protein scaffolds are gaining increasing interest as therapeutics.
Similarly to full-length antibodies, they can bind a target with a high binding affinity and …

Highlights•Structure-based strategies allow more-specific targeting of protein–protein
interactions (PPIs).•Interfering peptides (IPs) become a promising alternative to small …

Highlights•A variety of albumin-binding moieties (ABMs) have been developed for half-life
extension of short-lived drugs.•Various drugs can incorporate a selected ABM for in situ HSA …